A
Axion Reagents
Research-use amino-acid reagents with batch documentation and third-party HPLC certificates of analysis.
Victor Muraviev
London
CEO & Chairman, Axion Scientific Ltd.
Victor
Muraviev
I have directed Axion Scientific as CEO & Chairman since 2025.
I have worked in investments, particularly in equities and derivatives, since 2019, and have worked across performance pharmacology, biological adaptation, philosophy, and artificial intelligence.
- Axion Scientific
- Visit ↗
- Contact
- me@victorm.co.uk ↗
Reagents, analysis
and filtration.
Following years of experience in the peptide industry, I became Chief Executive Officer and Chairman of Axion Scientific Ltd in 2025. I direct strategy and operations across Axion Reagents, Chemical Analysis and Filtration, and lead the company’s internal research division.
B
Chemical Analysis
Ordered-reagent testing including TFA, pH, endotoxin, LC–MS, sterility and heavy-metals analysis.
C
Filtration
USP vials and laboratory filters, with manufacturer documentation provided where available.
Investments
Equities + derivatives
2019—present
From Tesla & Semis
to Nebius.
Started investing with TSLA and semiconductors.
Majority-TSLA portfolio from 2020.
Took time off for health.
Returned to active investing with a majority-NBIS portfolio.
Nebius Group NV / NBIS
A concentrated AI-infrastructure thesis.
Since returning to investments in 2024, I have centred my public-market strategy around Nebius Group using both equities and derivatives. The original thesis was that Arkady Volozh had moved from Yandex into a Western AI-infrastructure company while preserving much of the engineering base, experience and commercial network; Nebius also began with almost $2.5 billion in cash, little debt and a valuation below $10 billion. The sanctions environment therefore created an opportunity to buy into an elite AI-infrastructure company before the market repriced it.
I was one of the earliest public NBIS investors and commentators. I created the first dedicated NBIS subreddit and the first large NBIS-focused X account, @NBISStock, covering earnings, financing, AI infrastructure, subsidiaries including ClickHouse and Toloka, options positioning and valuation.
Nebius subsequently reached a 52-week high of $299.86, 19.90× my lowest documented entry. My ROI since returning to investments in 2024 exceeds 500% (6× gross).
- Lowest documented entry
- $15.07
- 52-week high
- $299.86
- Concentration
- 80–90%+
- External-capital ROI
- >500%
- Selected option
- +3,111.58%
- Selected option
- +1,167.00%
From $15.07: 19.90× gross / +1,889.78%
of invested public-equity and derivatives exposure for over a year
timing-aware lower bound since returning in 2024; balances omitted
The option figures are returns on individual positions, not on the portfolio as a whole. Account values are not published.
Artificial intelligence
ASI since 2017
OpenAI + Neuralink since 2019
Biological agency
and machine intelligence.
I have been bullish on artificial superintelligence since 2017 and have covered OpenAI and Neuralink since 2019. Before LLMs became the dominant route to advanced intelligence, I expected ASI to be reached primarily through the digitisation of biology and placed particular weight on Neuralink and brain–computer interfaces.
Despite advances in large language technology, BCIs remain a matter of interest in AI development, usage and alignment, and their future importance is likely to increase substantially.
“Before LLMs were popularised, I thought we’d reach ASI primarily by digitising biology.”
Biological research
Pharmacology
Growth factors
Connective tissue
Response, limits
and adaptation.
Performance pharmacology
I built an education and consulting business around performance-enhancing compounds. I helped clients understand cutting-edge and extreme applications of AAS, rhGH, peptides, insulin and ancillaries, alongside bloodwork, training and recovery.
PEDs are, at best, the tertiary determinant of bodybuilding success. Genetics and energy availability make growth possible; training and pharmacology provide additional stimulus; and response to pharmacology is itself substantially genetic.
01
rhGH → IGF-1
Plotting the upper end of the dose response.
I used extreme rhGH exposure to investigate endocrine and autocrine IGF-1 response. The results helped plot the upper end of the rhGH–IGF-1 curve and motivated a wider investigation of saturation, desensitisation, immunogenicity and why dose escalation ceases to produce a proportionate systemic response, illustrating its asymptotic nature in previously unexamined edge cases.
02
Tendon adaptation / arm wrestling
Tendon adaptation, mechanisms and applications.
My work covers tendon stiffness and high-tension, low-fatigue loading (Chris Beardsley); cross-sectional area, collagen synthesis and loading-bout refractoriness (Keith Baar); strain–time dose; and arm-wrestling-specific tendon targets, style-dependent loading and programming.
Background
Education, competition and further study.
- 2017—2024
- Kingston Grammar School Senior Prize for Philosophy, Religion & Ethics; Junior Prize for Design & Technology.
- Chess
-
2300+Speed chess ratingGlobal Top 100Three-Check / 2026Global Top 200Atomic Chess / 2020
Lichess.org
- Other certifications
- Advanced Neurobiology I, Peking University · Derivatives—Options & Futures, Interactive Brokers · Innovate & Regulate: Drug Research, Davidson College · Google Cloud Artificial Intelligence
Philosophy
Fields of interest
Philosophy.
- Mereology
- Ontology
- Epistemology
A browser-local document comparison tool for text, PDF, Word and common document formats by Victor. Files remain in the browser rather than being uploaded for processing.
Contact